Navigation Links
China Pharma Holdings, Inc. Reports Full Year 2009 Financial Results
Date:3/5/2010

9,949 2,838,679 TOTAL ASSETS $100,941,062 $75,471,837 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Trade accounts payable $3,957,923 $1,049,268 Accrued expenses 47,435 56,075 Accrued taxes payable 1,528,691 1,170,003 Other payables 58,191 42,813 Advances from customers 1,037,693 693,178 Other payables-related parties 75,741 75,741 Notes payable 3,802,726 2,480,231 Total Current Liabilities 10,508,400 5,567,309 Long-term research and development commitments 36,565 36,474 Total Liabilities 10,544,965 5,603,783 Stockholders' Equity Common stock - $0.001 par value; 60,000,000 shares authorized; 42,308,350 shares and 42,278,938 shares outstanding, respectively 42,308 42,279 Additional paid-in capital 21,178,114 21,066,338 Retained earnings 63,272,868 43,039,819 Accumulated other comprehensive income 5,902,807 5,719,618 Total Stockholders' Equity 90,396,097 69,868,054 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $100,941,062 $75,471,837 CHINA PHARMA HOLDINGS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME For the Years Ended December 31,
'/>"/>
SOURCE China Pharma Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. China Biologic Products to Present at the Rodman & Renshaw Annual China Investment Conference
2. China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results
3. China Nepstar Chain Drugstore Announces Annual Dividend
4. Chinas leading electronic systems design event to highlight next-generation medical, automotive and green power technologies
5. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
6. OrbusNeich Announces First Patient Enrolled in Randomized Clinical Trial of Genous(TM) Bio-engineered R stent(TM) in China
7. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
8. Candela Receives Registration Approval to Market Its Best-in-Class GentleMax and Alex TriVantage Lasers in China
9. Gorbec Pharmaceutical Services, Inc. Announces the Launch of Its GMP Analytical Laboratory in China
10. Chinas Basic Medical Insurance to Cover Sinobiopharmas Flagship Product
11. China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 Celsion Corporation (NASDAQ: ... data from its ongoing open-label Phase 2 DIGNITY ... Cancer (RCWBC).  The trial is designed to enroll ... is evaluating ThermoDox in combination with mild hyperthermia. ... eligible for evaluation of efficacy.  Based on data ...
(Date:7/24/2014)... HIGHLIGHTS:Q2 2014 Results (all percentage changes ... sales increased 3% to $701 million.  Sales grew organically by ... percentage point to sales growth. , By business unit, ... and 1% in SAFC Commercial. , Reported diluted EPS ... of 13%.  Adjusted diluted EPS in Q2 2014 was also ...
(Date:7/24/2014)... and VANCOUVER, British Columbia , ... OGXI ) announced today that the Company,s ... Thursday, August 7, 2014, and that the Company will ... p.m. ET that afternoon. Management will provide an overview ... general business update. To access the ...
Breaking Medicine Technology:Celsion Announces Positive Interim Data Update from its Phase 2 DIGNITY Study in Breast Cancer 2Celsion Announces Positive Interim Data Update from its Phase 2 DIGNITY Study in Breast Cancer 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 4Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 5Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 6Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 7Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 8Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 9Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 10Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 11Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 12Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 13Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 14Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 15Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 16Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 17Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 18Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 19Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 20Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 21Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 22OncoGenex to Report Financial Results for Second Quarter 2014 on August 7, 2014 2
... 26 Bristol-Myers Squibb,Company (NYSE: BMY ) ... in which treatment of antiviral-naive adult chronic hepatitis ... viral,load reduction than adefovir at 96 weeks -- ... viral load to undetectable,levels is a measure of ...
... ... C Clarification of Oncogenic Pathways Aids ... Benefit in Liver Transplantation, MILAN, April 26 , - Systems Biology Helps ... of the European,Association for the Study of the Liver (EASL), experts reported advances in,basic ...
Cached Medicine Technology:BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 2BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 3BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 4BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 5BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 6BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 7Basic Science Discoveries Yield Progress in Hepatology 2Basic Science Discoveries Yield Progress in Hepatology 3Basic Science Discoveries Yield Progress in Hepatology 4
(Date:7/24/2014)... The first-ever successful isolation and culture of ... been achieved by NFCR-supported scientist Daniel Haber, M.D., Ph.D., ... an important milestone on the road to individualized cancer ... for each patient. , “Tumors evolve in response ... genetic features that make them resistant to drugs. If ...
(Date:7/24/2014)... cancer involves exposing the patient or their tumor more ... X-rays. The radiation damages the cancer cells irreparably. Unfortunately, ... the skin over the site of the tumor, which ... and even skin cancer. As such finding ways to ... in the International Journal of Low Radiation, Faruck Lukmanul ...
(Date:7/24/2014)... Researchers have uncovered a way the malaria parasite ... at Washington University School of Medicine in St. ... including bacterial infections and tuberculosis. , The study ... , Many organisms, including the parasite that causes ... which play multiple roles in keeping organisms healthy, ...
(Date:7/24/2014)... July 24, 2014 July 22, ... in sealant and anesthesia reversal products to National ... help save young smiles. The donation of over ... Oraverse® was distributed to America’s ToothFairy Affiliate clinical ... vital oral health services. The America’s ToothFairy Affiliate ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Recently, Stwd.co.uk, a ... enriched its product line by adding many new designs of ... All outfits in the new collection come with big discounts. ... launching a special offer on all these fashionable items. They ... example, a pink V-neck strapless beading prom dress was previously ...
Breaking Medicine News(10 mins):Health News:New Blood Test Advances Individualized Cancer Therapy and Cuts Down on Need for Painful Biopsies 2Health News:Natural products from plants protect skin during cancer radiotherapy 2Health News:One route to malaria drug resistance found 2Health News:One route to malaria drug resistance found 3Health News:Septodont Donation Helps Children in Need 2Health News:Cheap Wedding Dresses Are Offered by Stwd.co.uk at Low Prices 2
... , , , SOUTH SAN FRANCISCO, Calif., ... scientific presentations at the International Society on Thrombosis and ... its investigational antiplatelet drug elinogrel, a P2Y(12) ADP receptor ... oral Factor Xa inhibitor anticoagulant antidote in pre-clinical development, ...
... most people sidelined for long, study shows , FRIDAY, July ... full participation in sports or activity within six months of ... , U.S. researchers examined questionnaires filled out by 165 patients, ... performed by a single surgeon between July 1, 2004 and ...
... though, that screenings remain vital , THURSDAY, July 9 (HealthDay ... a screening mammogram is unlikely to ever cause a problem, ... overdiagnosis rate of 35 percent came from an examination of ... researchers and published online Thursday in BMJ . , ...
... (NYSE: WPI ), a leading specialty pharmaceutical company, ... quarter 2009 financial results on Wednesday, July 29, 2009 prior ... Company will also host a conference call and webcast at ... discuss its financial results and provide an update on the ...
... INDIANAPOLIS, July 10 Eli Lilly and Company ... this, its 35th year of support for the Indiana Black Expo (IBE) ... and a presence at the IN Shape Indiana Black ... stay healthy in these uncertain economic times. , , An example ...
... PALM CITY, Fla., July 10 Connectyx Technologies Holdings Group, ... Company is looking to establish itself as the market leader ... by Connectyx CEO, Ronn Schuman during yesterday,s Nationwide Teleconference. ... a goal to reach 1.2 million members by the end ...
Cached Medicine News:Health News:Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 2Health News:Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 3Health News:Shoulder Surgery Helps Athletes Get Back in the Game 2Health News:More Mammograms May Mean More 'Harmless' Cancers 2Health News:Watson to Host Second Quarter 2009 Earnings Conference Call and Webcast 2Health News:Lilly Celebrates Its 35th Year as a Supporter of the Indiana Black Expo 2Health News:Lilly Celebrates Its 35th Year as a Supporter of the Indiana Black Expo 3Health News:Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 2Health News:Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 3
Full Handle Laseredge Implant Blade Knife, 5.2 mm angled bevel up. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
Full Handle Laseredge Implant Blade Knife, 4.0 mm angled bevel up. Blade dimension: 15.2 mm x 4.0 mm x 3.0 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel down. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Crescent Blade Knife, straight. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Medicine Products: